Targeting toll-like receptor 4 (TLR4) and the NLRP3 inflammasome: Novel and emerging therapeutic targets for hyperuricaemia nephropathy. Biomol Biomed. 2023;24(4):688–697. doi:10.17305/bb.2023.9838